**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 47376

**Manuscript Type:** REVIEW

**Current status of adjuvant chemotherapy for gastric cancer**

Kim IH. Adjuvant chemotherapy for gastric cancer

In-Hwan Kim

**In-Hwan Kim,** Department of Surgery, Catholic University of Daegu, Daegu 42472, South Korea

**ORCID number:** In-Hwan Kim (0000-0003-3287-4100).

**Author contributions:** Kim IH performed the review of the literature and wrote the paper.

**Conflict-of-interest statement:** The author declares no conflict of interests for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: In-Hwan Kim, MD, PhD, Assistant Professor,** Department of Surgery, Catholic University of Daegu School of Medicine, 33, 17-gil, Duryugongwon-ro, Nam-gu, Daegu 42472, South Korea. kih2yk@cu.ac.kr

**Telephone:** +82-53-6504065

**Fax:** +82-53-6247185

**Received:** March 20,2019

**Peer-review started:** March 22, 2019

**First decision:** June 5, 2019

**Revised:** July 18, 2019

**Accepted:** August 20, 2019

**Article in press:** August 21, 2019

**Published online:** September 15, 2019

**Abstract**

Although radical gastrectomy is a standard treatment for advanced gastric cancer, recurrence remains high. After several large-scale controlled studies have shown the beneficial effects of adjuvant chemotherapy, that treatment emerged as a standard option for advanced gastric cancer after gastrectomy. However, various guidelines from different countries have suggested different adjuvant chemotherapies. Understanding the differences between guidelines is very important for investigating further therapeutic strategies. Fortunately, because there are many ongoing studies about new regimens for adjuvant treatment, it is expected that patients with gastric cancer after surgery will have better outcome.

**Key words:** Gastric cancer; Adjuvant chemotherapy; Perioperative chemotherapy; Chemoradiotherapy; Guidelines

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** There are differences in preferred adjuvant therapy for gastric cancer according to the guidelines from different countries. These include the National Comprehensive Cancer Network recommending chemoradiotherapy, the European Society for Medical Oncology recommending perioperative chemotherapy, and the Japanese recommending postoperative chemotherapy. Understanding the differences between guidelines can help in the future investigations of further regimens for adjuvant treatment of gastric cancer.

Kim IH.Current status of adjuvant chemotherapy for gastric cancer. *World J Gastrointest Oncol* 2019; 11(9): 679-685 URL: https://www.wjgnet.com/1948-5204/full/v11/i9/679.htm DOI: https://dx.doi.org/10.4251/wjgo.v11.i9. 679

**INTRODUCTION**

Although radical gastrectomy is a standard treatment for advanced gastric cancer, recurrence is a critical issue for long-term survival of patients. Gastric cancer is still one of the most common causes of death due to malignancy[1]. In the past, most researchers mentioned in their reviews that adjuvant treatment was not beneficial for improving survival after gastric cancer surgery. Some studies had found that adjuvant therapies did not improve the prognosis of patients with gastric cancer[2,3].

After the 2000s, several large-scale controlled studies showed beneficial effects of adjuvant chemotherapy on the survival of patients with gastric cancer[4,5]. These studies demonstrated better survival rates for patients who had received adjuvant therapies after gastrectomy for gastric cancer, as compared with patients who received surgery alone. Many subsequent studies also found the beneficial effects of adjuvant chemotherapy for patients with gastric cancer[6,7]. Therefore, adjuvant chemotherapy for gastric cancer has gained both research and clinical attention in the last 20 years, and it has become one of the standard treatment options for advanced gastric cancer after gastrectomy.

However, adjuvant therapies for gastric cancers are developed and studied separately among the various countries, without international guidelines. These various guidelines have suggested different adjuvant chemotherapies (Table 1). The differences among each might be the result of differences in race, epidemiology, etiologic factor, diagnostic tool, and clinical situation[8].

The purpose of this review is to summarize the previous studies about adjuvant chemotherapy for gastric cancer, describe the present treatment guidelines with regional differences, and discuss the ongoing studies and new regimens for adjuvant treatment of gastric cancer.

**PREVIOUS STUDIES ON ADJUVANT CHEMOTHERAPY FOR GASTRIC CANCER**

The SWOG INT-0116 trial by Macdonald *et al*[4] in 2001 was the first large-scale controlled study that provided positive results of adjuvant chemotherapy for gastric cancer. The investigators had made a comparison between surgery plus postoperative chemoradiotherapy and surgery alone for 556 patients with adenocarcinoma at the stomach or gastroesophageal junction. The results showed better overall and relapse-free survivals in the chemoradiotherapy group. However, that study had been criticized by many Asian researchers, in the aspect of low rates of D2 lymph node dissection. Most Asian surgeons believed that D2 lymph node dissection should be performed for locally advanced gastric cancer. Those authors have mentioned that results of the SWOG INT-0116 trial should be validated in patients who have undergone D2 lymph node dissection[9,10]. Despite its limitation, however, the SWOG INT-0116 trial has played a key role in furthering efforts to investigate postoperative therapy for gastric cancer. Its results are supported by several studies showing that postoperative chemotherapy plays a significant role in compensating undertreated surgery[11,12].

In 2006, the MAGIC trial showed that perioperative adjuvant chemotherapy using a triplet combination regimen produced a successful result in improving survival rates of patients with gastric cancer[5]. Ultimately, that trial supported a new concept in terms of using both preoperative and postoperative chemotherapy for gastric cancer. Neoadjuvant chemotherapy also has some advantages, such as relatively high dose with better compliance and down-staging before surgery[13,14]. After the MAGIC trial, perioperative chemotherapy became a standard treatment for locally advanced gastric cancer in the European society[15].

In Asian countries, radical gastrectomy with D2 lymph node dissection has been considered as a standard treatment for advanced gastric cancer applied earlier than that in Western countries. Therefore, many Asian studies have investigated postoperative adjuvant chemotherapy regimens after D2 lymph node dissection without radiotherapy or neoadjuvant therapy. The ACTS-GC trial has reported better survival rates with S-1 monotherapy in Japan[16,17]. The CLASSIC trial has shown beneficial effect of the capecitabine plus oxaliplatin chemotherapy regimen (XELOX) in Korea[18,19]. Both of these two regimens have been widely used in Asian countries for advanced gastric cancer after curative resection[20]. They have also been adopted in Western guidelines as a treatment option[15,21]. Kim *et al*[22] have reported that there are no differences in survival rates for patients with gastric cancer at earlier stages between these two chemotherapeutic regimens, although XELOX chemotherapy is more effective than S-1 for patients with higher stages of gastric cancer, including 3B and 3C.

**GUIDELINES OF ADJUVANT TREATMENT FOR GASTRIC CANCER**

There are several strategies for adjuvant treatments available, including chemoradiation, perioperative chemotherapy, and postoperative chemotherapy. Chemoradiation consists of intravenous 5-fluorouracil (5-FU) and irradiation being administered postoperatively. Oral administration of capecitabine is also accepted in combination with irradiation as an alternative to infused 5-FU[21]. Recommended regimens for perioperative chemotherapies are combination of epirubicin, cisplatin, and 5-FU (known as ECF) and its modification that includes the so-called ECX regimen of epirubicin, cisplatin, capecitabine, and EOX, which is epirubicin, oxaliplatin, capecitabine[15]. Postoperative adjuvant chemotherapies with S-1 monotherapy, or XELOX chemotherapy are accepted as treatment options for advanced gastric cancer after curative resection[20].

Because adjuvant treatments for advanced gastric cancer after gastrectomy were developed separately among countries, there are many differences in recommendations from the guidelines according to the various countries they were developed in.

***National Comprehensive Cancer Network clinical practice guidelines***

The National Comprehensive Cancer Network (NCCN) clinical practice guidelines provide standard treatment strategies for many cancers, including breast and colorectal cancers, for use not only in United States but also around the world[21]. Although the incidence of gastric cancer is low in the United States, its mortality is still high. Therefore, the NCCN guidelines for treatment of gastric cancer have some differences compared to others[23]. Although the NCCN guidelines agree that D2 lymph node dissection is associated with low mortality and reasonable survival benefit, they recommend gastrectomy with D1 or modified D2 lymph node dissection and emphasize that D2 lymph node dissection should be performed only by experienced surgeons because of its technical difficulty[24,25]. They recommend postoperative chemoradiation for cases that have not received preoperative chemotherapy, although the evidence of efficacy of using chemotherapy after R1 or R2 resection is unclear[26]. They also recommend perioperative chemotherapy, according to results from the MAGIC trial. For the postoperative chemotherapy, the NCCN guidelines state that it is difficult to apply results of the ACTS-GC and CLASSIC trials because D2 lymph node dissection is rarely performed in many of the United States cancer centers. They only include postoperative chemotherapy with XELOX as an option for cases that have undergone D2 or modified D2 dissection, with emphasis on chemoradiation[9]. S-1 is still regarded as an investigational agent in north America.

***European Society for Medical Oncology clinical practice guidelines***

The European Society for Medical Oncology (ESMO) clinical practice guidelines suggest that D2 lymph node dissection should be performed for patients with stage IB-III gastric cancer. They recommend perioperative chemotherapy preferentially. Although fluoropyrimidine plus platinum-based doublet or triplet regimens are reasonable, combination of fluorouracil, epirubicin, and cisplatin is mostly recommended with strong evidence[27]. The ESMO guidelines recommend postoperative chemoradiotherapy or chemotherapy for patients who have undergone gastrectomy without preoperative therapy. Postoperative chemotherapy has been adopted according to results from the ACTS-GC and CLASSIC trials. Although postoperative chemoradiotherapy is a standard treatment in the United States, they state that this therapeutic option has not gained acceptance in Europe because of toxicity and difference in surgical quality. However, they recommend chemoradiotherapy in the case of suboptimal surgery with less lymphadenectomy or suspicious micrometastasis[26,28].

***Japanese gastric cancer treatment guidelines***

The Japanese gastric cancer treatment guidelines suggest that standard gastrectomy is curative gastric resection with D2 lymph node dissection for stage 1B or higher gastric cancer[20]. They recommend postoperative chemotherapy with S-1 monotherapy preferentially because the efficacy of S-1 has been proven in Japan. Although the CLASSIC trial showed good result from XELOX, oxaliplatin has not been approved for gastric cancer in Japan. After Japanese studies with oxaliplatin were published, combination therapy of capecitabine or S-1 plus oxaliplatin was adopted as an option for postoperative chemotherapy[29,30]. Because curative radical gastrectomy with D2 lymph node dissection has been the standard treatment in Asian countries for a long time, the Japanese guidelines did not mention radiotherapy as an adjuvant treatment at all, even for cases of noncurative resection.

**ONGOING STUDIES AND NEW REGIMENS FOR ADJUVANT CHEMOTHERAPY**

During the last 20 years, a variety of adjuvant therapies for gastric cancers have been investigated. Although the development of adjuvant treatment has been different among countries, there are several efforts to adopt different therapeutic strategies from the others. Most importantly, surgical treatment has become more standardized; for example, the European society has already accepted D2 lymph node dissection as a standard treatment. The NCCN clinical practice guidelines have also provided recommendation of D2 dissection in certain situations[15,20,21].

Today, several ongoing Asian studies, in Korea and China in particular, are investigating the efficacy of perioperative chemotherapy and/or postoperative chemoradiotherapy[31]. Studies investigating new regimens of combination with S-1 are ongoing. In Japan, the safety and feasibility of S-1 plus cisplatin as an adjuvant chemotherapy has been proven[32], and a phase II study of S-1 plus oxaliplatin as combination therapy has also been approved[30]. In China, a large-scale randomized controlled trial (referred to as the RESCUE-GC) is ongoing, to investigate the efficacy of S-1 plus oxaliplatin as adjuvant therapy for gastric cancer[33]. There is also a phase III study evaluating the significance of preoperative chemoradiation therapy for locally advanced gastric cancer. This study is designed to investigate addition of radiotherapy to the MAGIC trial[34].

After the ToGA trial found survival gain for advanced gastric cancer with trastuzumab combination[35], the significance of combination therapies with molecular target agents gained much interest in the field of adjuvant treatment. However, targeted agents have failed to show their efficacies as adjuvant treatment for gastric cancer. The ST03 trial showed no significant difference between the group who received chemotherapy alone and the group who received combination of chemotherapy plus bevacizumab but did find an increased rate of anastomotic leakage in the combination group[36]. To date, several studies are ongoing to investigate efficacies of target therapeutic agents as adjuvant treatment for gastric cancer[31].

Although adjuvant treatments have been developed and are widely used, recurrence and metastasis are still critical problems for survival of patients after gastrectomy. Drug resistance is one of the most important causes of therapeutic failure in gastric cancer patients. Although many researchers have studied the mechanisms of drug resistance in gastric cancer, the regulation of these mechanisms has not been completely elucidated. Recently, several researchers have reported precise mechanisms of chemoresistance in gastric cancer and showed the possibility of advances in prediction of failure of chemotherapeutic agents[37,38]. These efforts can lead to the future development of individual therapeutic plans for patients with gastric cancer and novel strategies to overcome chemoresistance.

**CONCLUSION**

After the development of adjuvant chemotherapy for gastric cancer, there has been a years-long steady improvement in survival after gastric cancer surgery. In accordance with the many ongoing studies investigating new regimens as adjuvant therapy for gastric cancer, better prognosis of patients after surgery is expected in the future.

Because there are several differences in the various national and regional guidelines, it is very important to know and understand their differences and to make an effort to provide better treatment strategies by communication among each other. Unfortunately, this review cannot suggest the best strategy for the patients with gastric cancer; this is due to the results of studies between Western and Asian countries being difficult to compare directly in the present situation. For further advances and worldwide consensus in adjuvant treatment of gastric cancer, new studies are warranted, including studies about racial or genetic differences in patients with gastric cancer, worldwide studies to determine surgical and therapeutic standards, and studies to investigate the mechanisms of the oncology of gastric cancer.

**REFERENCES**

1 **Torre LA**, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; **65**: 87-108 [PMID: 25651787 DOI: 10.3322/caac.21262]

2 **Nakajima T**. Review of adjuvant chemotherapy for gastric cancer. *World J Surg* 1995; **19**: 570-574 [PMID: 7676702 DOI: 10.1007/BF00294725]

3 **Hohenberger P**, Gretschel S. Gastric cancer. *Lancet* 2003; **362**: 305-315 [PMID: 12892963 DOI: 10.1016/S0140-6736(03)13975-X]

4 **Macdonald JS**, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001; **345**: 725-730 [PMID: 11547741 DOI: 10.1056/NEJMoa010187]

5 **Cunningham D**, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006; **355**: 11-20 [PMID: 16822992 DOI: 10.1056/NEJMoa055531]

6 **GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group,** Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737 [PMID: 20442389 DOI: 10.1001/jama.2010.534]

7 **Ychou M**, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol* 2011; **29**: 1715-1721 [PMID: 21444866 DOI: 10.1200/JCO.2010.33.0597]

8 **Ueno T**, Iida M, Yoshino S, Takeda S, Kubota H, Higashida M, Oka Y, Tsuruta A, Matsumoto H, Nagano H. East Versus West: Differences in Surgical Management in Asia Compared with Europe and North America. *Surg Clin North Am* 2017; **97**: 453-466 [PMID: 28325197 DOI: 10.1016/j.suc.2016.12.002]

9 **Lee J**, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. *J Clin Oncol* 2012; **30**: 268-273 [PMID: 22184384 DOI: 10.1200/JCO.2011.39.1953]

10 **Kim S**, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. *Int J Radiat Oncol Biol Phys* 2005; **63**: 1279-1285 [PMID: 16099596 DOI: 10.1016/j.ijrobp.2005.05.005]

11 **Lordick F**, Siewert JR. Recent advances in multimodal treatment for gastric cancer: a review. *Gastric Cancer* 2005; **8**: 78-85 [PMID: 15864714 DOI: 10.1007/s10120-005-0321-z]

12 **Hundahl SA**, Macdonald JS, Benedetti J, Fitzsimmons T; Southwest Oncology Group and the Gastric Intergroup. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. *Ann Surg Oncol* 2002; **9**: 278-286 [PMID: 11923135 DOI: 10.1007/BF02573066]

13 **Allum WH**, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. *J Clin Oncol* 2009; **27**: 5062-5067 [PMID: 19770374 DOI: 10.1200/JCO.2009.22.2083]

14 **Schuhmacher C**, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. *J Clin Oncol* 2010; **28**: 5210-5218 [PMID: 21060024 DOI: 10.1200/JCO.2009.26.6114]

15 **Smyth EC**, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2016; **27**: v38-v49 [PMID: 27664260 DOI: 10.1093/annonc/mdw350]

16 **Sakuramoto S**, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med* 2007; **357**: 1810-1820 [PMID: 17978289 DOI: 10.1056/NEJMoa072252]

17 **Sasako M**, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. *J Clin Oncol* 2011; **29**: 4387-4393 [PMID: 22010012 DOI: 10.1200/JCO.2011.36.5908]

18 **Bang YJ**, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. *Lancet* 2012; **379**: 315-321 [PMID: 22226517 DOI: 10.1016/S0140-6736(11)61873-4]

19 **Noh SH**, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 2014; **15**: 1389-1396 [PMID: 25439693 DOI: 10.1016/S1470-2045(14)70473-5]

20 **Japanese Gastric Cancer Association.**. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* 2017; **20**: 1-19 [PMID: 27342689 DOI: 10.1007/s10120-016-0622-4]

21 **Ajani JA**, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2016; **14**: 1286-1312 [PMID: 27697982 DOI: 10.6004/jnccn.2016.0137]

22 **Kim IH**, Park SS, Lee CM, Kim MC, Kwon IK, Min JS, Kim HI, Lee HH, Lee SI, Chae H. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study. *Ann Surg Oncol* 2018; **25**: 1176-1183 [PMID: 29450755 DOI: 10.1245/s10434-018-6375-z]

23 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; **63**: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]

24 **Schwarz RE**, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. *Ann Surg Oncol* 2007; **14**: 317-328 [PMID: 17094022 DOI: 10.1245/s10434-006-9218-2]

25 **Songun I**, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. *Lancet Oncol* 2010; **11**: 439-449 [PMID: 20409751 DOI: 10.1016/S1470-2045(10)70070-X]

26 **Dikken JL**, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, Boot H, Putter H, Peeters KC, van de Velde CJ, Verheij M. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. *J Clin Oncol* 2010; **28**: 2430-2436 [PMID: 20368551 DOI: 10.1200/JCO.2009.26.9654]

27 **Cunningham D**, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 2008; **358**: 36-46 [PMID: 18172173 DOI: 10.1056/NEJMoa073149]

28 **Stiekema J**, Trip AK, Jansen EP, Boot H, Cats A, Ponz OB, Verheij M, van Sandick JW. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. *Ann Surg Oncol* 2014; **21**: 1107-1114 [PMID: 24306660 DOI: 10.1245/s10434-013-3397-4]

29 **Fuse N**, Bando H, Chin K, Ito S, Yoshikawa T, Tsuburaya A, Terashima M, Kawashima Y, Fukunaga T, Gotoh M, Emi Y, Yoshida K, Oki E, Takahashi S, Kuriki H, Sato K, Sasako M. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study. *Gastric Cancer* 2017; **20**: 332-340 [PMID: 26956689 DOI: 10.1007/s10120-016-0606-4]

30 **Shitara K**, Chin K, Yoshikawa T, Katai H, Terashima M, Ito S, Hirao M, Yoshida K, Oki E, Sasako M, Emi Y, Tsujinaka T. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. *Gastric Cancer* 2017; **20**: 175-181 [PMID: 26626800 DOI: 10.1007/s10120-015-0581-1]

31 **Aoyama T**, Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. *Surg Today* 2017; **47**: 1295-1302 [PMID: 28251375 DOI: 10.1007/s00595-017-1493-y]

32 **Takahari D**, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, Kinoshita T, Yasui H, Terashima M, Goto M, Tanigawa N, Shirao K, Sano T, Sasako M. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. *Cancer Chemother Pharmacol* 2011; **67**: 1423-1428 [PMID: 20809123 DOI: 10.1007/s00280-010-1432-8]

33 **Hu X**, Chen L, Du Y, Fan B, Bu Z, Wang X, Ye Y, Zhang Z, Xiao G, Li F, He Q, Li G, Shen X, Xiong B, Zhu L, Liu J, Liu L, Wu T, Zhou J, Zhang J, Zhao G, Wang X, Liang P, Wang X, Zhang Y, Wu X, Zhang J, Ji X, Zong X, Fu T, Jia Z, Ji J. Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial. *Chin J Cancer Res* 2017; **29**: 144-148 [PMID: 28536493 DOI: 10.21147/j.issn.1000-9604.2017.02.07]

34 **Leong T**, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D, Simes J, Zalcberg J, Haustermans K, Lordick F, Schuhmacher C, Swallow C, Darling G, Wong R. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). *BMC Cancer* 2015; **15**: 532 [PMID: 26194186 DOI: 10.1186/s12885-015-1529-x]

35 **Bang YJ**, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; **376**: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]

36 **Cunningham D**, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. *Lancet Oncol* 2017; **18**: 357-370 [PMID: 28163000 DOI: 10.1016/S1470-2045(17)30043-8]

37 **Marin JJ**, Al-Abdulla R, Lozano E, Briz O, Bujanda L, Banales JM, Macias RI. Mechanisms of Resistance to Chemotherapy in Gastric Cancer. *Anticancer Agents Med Chem* 2016; **16**: 318-334 [PMID: 26234359 DOI: 10.2174/1871520615666150803125121]

38 **Riquelme I**, Letelier P, Riffo-Campos AL, Brebi P, Roa JC. Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer. *Int J Mol Sci* 2016; **17**: 424 [PMID: 27011182 DOI: 10.3390/ijms17030424]

**P-Reviewer:** Marin J, Izbicki J, Kupeli S **S-Editor:** Zhang L **L-Editor:** A **E-Editor:** Qi LL

**Specialty type:** Oncology

**Country of origin:** South Korea

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Comparison of guidelines of adjuvant chemotherapy for gastric cancer**

|  |  |  |
| --- | --- | --- |
| **Guideline** | **Methods of adjuvant therapy** | **Regimen** |
| NCCN | Postoperative chemoradiation (preferred) | 5-FU plus irradiation |
| Perioperative chemotherapy | ECF |
| Modification of ECF |
| Postoperative chemotherapy (only after D2 lymph node dissection) | XELOX |
| Capecitabine plus cisplatin |
| ESMO | Perioperative chemotherapy (preferred) | ECF |
| Modification of ECF |
| Postoperative chemotherapy (patients without preoperative therapy) | S-1 monotherapy |
| XELOX |
| Postoperative chemoradiation (for undertreatment surgery) | 5-FU plus irradiation |
| Japanese | Postoperative chemotherapy | S-1 monotherapy (preferred) |
| S-1 plus oxaliplatin |
| XELOX |

5-FU: 5-Fluorouracil; ECF: Epirubicin, cisplatin, and 5-fluorouracil; ESMO: European Society for Medical Oncology; NCCN: National Comprehensive Cancer Network; XELOX: Capecitabine plus oxaliplatin.